Manifold Bio is a technology company.
Manifold Bio has raised $45.0M across 2 funding rounds.
Manifold Bio has raised $45.0M in total across 2 funding rounds.
Manifold Bio has raised $45.0M in total across 2 funding rounds.
Manifold Bio's investors include Off the Chain Capital, Triatomic Capital, Jonno Elliott, FAST — by GETTYLAB.
Manifold Bio is a biotechnology company developing tissue-targeted biologics using a proprietary high-throughput in vivo (HTV) discovery engine that integrates massively multiplexed in vivo screening with AI-powered protein design.[1][2][5] This platform addresses key limitations of traditional in vitro methods by directly testing and optimizing biologics—like antibodies and shuttles—for pharmacokinetics, biodistribution, and tissue specificity in living systems, enabling precise delivery across modalities for neurological diseases and other areas.[1][4] It serves pharmaceutical partners and pursues internal programs, solving the challenge of poor tissue penetration for biologics; the company has raised $78.18M, achieved Series A-II stage, and secured a partnership with Roche for brain shuttles, signaling strong growth momentum.[3][4][5]
Manifold Bio was founded in 2019 in Allston, Massachusetts, emerging from innovations in the Church Lab at Harvard Medical School, where co-founder Gleb Kuznetsov, Ph.D. (current CEO), advanced technologies like mCodes—molecular barcodes for tracking thousands of biologics in vivo.[2][5] The idea stemmed from "Super Evolution" experiments using gene synthesis, error-prone PCR, and FlowSeq to evolve brighter GFP variants, scaling to screen over 100,000 antibodies in single in vivo experiments—far beyond industry norms of testing one at a time.[2] Early traction included developing over 150 mCodes by end-2021, boosting tracking capacity by two orders of magnitude, and focusing on T-cell engagers (TCEs) for oncology before pivoting to tissue-targeted shuttles; seed funding and an initial team solidified the platform's reality.[2][5]
Manifold Bio stands out through these key innovations:
Manifold Bio rides the convergence of AI-driven drug discovery and in vivo biologics engineering, capitalizing on advances in protein design, barcoding, and multiplexing to unlock tissue-specific delivery—a bottleneck for 90%+ of biologics failing clinical translation due to poor targeting.[1][2][4] Timing is ideal amid the AI biotech boom (510+ companies in the space) and immunotherapy breakthroughs like CAR-T, with market forces like Roche's Phase II BBB shuttle data (e.g., trontinemab via TfR) proving demand for better portals.[4][5] By generating massive translational in vivo data, Manifold influences the ecosystem as a platform therapeutics leader, enabling Big Pharma partnerships and internal pipelines that could expand biologics to intractable areas like neurology, reducing development risks and costs.[3][4]
Manifold Bio is poised to scale its HTV engine into a multi-program powerhouse, advancing internal tissue-targeted candidates and deepening partnerships like Roche's for brain shuttles while expanding mShuttle libraries across modalities.[1][3][4] Trends like AI integration with real-world data and precision oncology will accelerate its trajectory, potentially yielding first-in-class therapeutics by resolving delivery challenges that have stalled the field. As leadership bolsters operations, expect broader ecosystem impact through licensed tech and novel drugs, transforming Manifold from platform innovator to delivery dominator—echoing its founding vision of measuring biology directly to conquer in vivo complexity.[2][3]
Manifold Bio has raised $45.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $40.0M Series A | Off the Chain Capital, Triatomic Capital, Jonno Elliott | |
| Sep 1, 2020 | $5.0M Seed | FAST — by GETTYLAB |